CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., today announced the appointment of Roche executive, Dan Malarek, as Chief Executive Officer (CEO). Malarek succeeds Brian Alexander, M.D., who will take on a senior leadership role in Roche’s Pharma Research and Development based in Boston.
Malarek has more than 15 years of experience in the diagnostics industry. Since January 2021, he has served as Global Head of Marketing & Customer Insights at Roche Diagnostics. Prior to this, he held multiple roles within Roche Diagnostics across various geographies with both global and local responsibilities.
“Dan’s depth of experience in product development combined with his passion for serving customers makes him the perfect leader to take Foundation Medicine forward and accelerate the company’s mission of transforming cancer care,” said Matt Sause, CEO Roche Diagnostics. “We also want to thank Brian for his leadership and many contributions and wish him the best in his new role.”
Commenting on his appointment, Dan Malarek said, “I am honored to serve as Foundation Medicine’s new CEO. Foundation Medicine is an extraordinary company that plays a critical role in empowering personalized cancer treatment solutions.”
Foundation Medicine is an independent affiliate of the Roche Group.
About Foundation Medicine: Your Essential Partner in Cancer Care
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.
